MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 463305 | Name: This product is removed
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

This product is removed

Chemical Structure

This product is removed
This product is removed
CAS#1632051-40-1

Theoretical Analysis

MedKoo Cat#: 463305

Name: This product is removed

CAS#: 1632051-40-1

Chemical Formula: C25H35N3O2

Exact Mass: 409.2729

Molecular Weight: 409.57

Elemental Analysis: C, 73.31; H, 8.61; N, 10.26; O, 7.81

Price and Availability

Size Price Availability Quantity
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
This product is removed
IUPAC/Chemical Name
1-(2-((3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl)-1H-pyrazole-4-carbonitrile
InChi Key
HARRKNSQXBRBGZ-GVKWWOCJSA-N
InChi Code
InChI=1S/C25H35N3O2/c1-24(30)9-7-18-17(11-24)3-4-20-19(18)8-10-25(2)21(20)5-6-22(25)23(29)15-28-14-16(12-26)13-27-28/h13-14,17-22,30H,3-11,15H2,1-2H3/t17-,18+,19-,20-,21+,22-,24-,25+/m1/s1
SMILES Code
C[C@]12[C@]([H])([C@]3([C@@]([H])([C@@]4([C@]([H])(CC3)C[C@](CC4)(C)O)[H])CC2)[H])CC[C@@H]1C(CN5C=C(C#N)C=N5)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 409.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Althaus AL, Ackley MA, Belfort GM, Gee SM, Dai J, Nguyen DP, Kazdoba TM, Modgil A, Davies PA, Moss SJ, Salituro FG, Hoffmann E, Hammond RS, Robichaud AJ, Quirk MC, Doherty JJ. Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator. Neuropharmacology. 2020 Sep 22;181:108333. doi: 10.1016/j.neuropharm.2020.108333. Epub ahead of print. PMID: 32976892. 2: Schoretsanitis G, Spigset O, Stingl JC, Deligiannidis KM, Paulzen M, Westin AA. The impact of pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-analysis. Expert Opin Drug Metab Toxicol. 2020 May;16(5):431-440. doi: 10.1080/17425255.2020.1750598. Epub 2020 Apr 10. PMID: 32238008; PMCID: PMC7323120. 3: Gunduz-Bruce H, Kanes SJ, Zorumski CF. Trial of SAGE-217 in Patients with Major Depressive Disorder. Reply. N Engl J Med. 2019 Nov 28;381(22):2179. doi: 10.1056/NEJMc1913170. PMID: 31774969. 4: Rosenblat JD. Trial of SAGE-217 in Patients with Major Depressive Disorder. N Engl J Med. 2019 Nov 28;381(22):2178-2179. doi: 10.1056/NEJMc1913170. PMID: 31774968. 5: Gunduz-Bruce H, Silber C, Kaul I, Rothschild AJ, Riesenberg R, Sankoh AJ, Li H, Lasser R, Zorumski CF, Rubinow DR, Paul SM, Jonas J, Doherty JJ, Kanes SJ. Trial of SAGE-217 in Patients with Major Depressive Disorder. N Engl J Med. 2019 Sep 5;381(10):903-911. doi: 10.1056/NEJMoa1815981. PMID: 31483961. 6: Hoffmann E, Nomikos GG, Kaul I, Raines S, Wald J, Bullock A, Sankoh AJ, Doherty J, Kanes SJ, Colquhoun H. SAGE-217, A Novel GABAA Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies. Clin Pharmacokinet. 2020 Jan;59(1):111-120. doi: 10.1007/s40262-019-00801-0. PMID: 31338688; PMCID: PMC6994455. 7: Ragguett RM, Tamura JK, McIntyre RS. Keeping up with the clinical advances: depression. CNS Spectr. 2019 Aug;24(S1):25-37. doi: 10.1017/S1092852919001159. Erratum in: CNS Spectr. 2019 Aug;24(S1):84. PMID: 31248466. 8: Frieder A, Fersh M, Hainline R, Deligiannidis KM. Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development. CNS Drugs. 2019 Mar;33(3):265-282. doi: 10.1007/s40263-019-00605-7. PMID: 30790145; PMCID: PMC6424603. 9: Wilkinson ST, Sanacora G. A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems. Drug Discov Today. 2019 Feb;24(2):606-615. doi: 10.1016/j.drudis.2018.11.007. Epub 2018 Nov 14. PMID: 30447328; PMCID: PMC6397075. 10: Martinez Botella G, Salituro FG, Harrison BL, Beresis RT, Bai Z, Blanco MJ, Belfort GM, Dai J, Loya CM, Ackley MA, Althaus AL, Grossman SJ, Hoffmann E, Doherty JJ, Robichaud AJ. Neuroactive Steroids. 2. 3α-Hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5β-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (γ-Aminobutyric Acid)A Receptor. J Med Chem. 2017 Sep 28;60(18):7810-7819. doi: 10.1021/acs.jmedchem.7b00846. Epub 2017 Aug 17. PMID: 28753313. 11: Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII). Epilepsia. 2017 Feb;58(2):181-221. doi: 10.1111/epi.13634. Epub 2017 Jan 23. PMID: 28111749. 12: Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII). Epilepsy Res. 2015 Mar;111:85-141. doi: 10.1016/j.eplepsyres.2015.01.001. Epub 2015 Jan 19. PMID: 25769377.